AdCom chair bows out of meeting under fire

Share this article:
Sidney Wolfe
Sidney Wolfe

Under pressure from Public Citizen and FDA, Dermatologic and Ophthalmic Drugs Advisory Committee chair Lynn Drake withdrew her acceptance of an invitation to provide a presentation to industry on winning a favorable panel endorsement.

On Oct. 24, Public Citizen Health Research Group senior advisor Sidney Wolfe complained to FDA about a conference brochure touting her presentation under the title, “FDA Advisory Committee Prep: Real World Best Practices to Achieve Favorable Recommendations.”

This, Wolfe told FDA, “seriously undermines and demeans the important FDA advisory committee process, particularly when the chair seeks to help drug companies get drugs approved.”

Reached by Reuters, Drake said she had not fully understood the nature of the meeting. “It was my understanding that this was an educational program,” she said, adding that she was neither offered nor asked for payment beyond her expenses.

FDA was contacted prior to Drake accepting the invitation to make the presentation, she said, and did not object. “It appears that Dr. Drake was not given a full understanding by the conference organizers of how she and her role at this conference would be characterized,” the agency said in a statement.

Wolfe said the episode demonstrated the need for better FDA ethics training for outside advisors.

Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro